eCite Digital Repository
Once-yearly zoledronic acid and change in abdominal aortic calcification over 3 years in postmenopausal women with osteoporosis: results from the HORIZON Pivotal Fracture Trial
Citation
Cai, G and Keen, HI and Host, LV and Aitken, D and Laslett, LL and Winzenberg, T and Wluka, AE and Black, D and Jones, G, Once-yearly zoledronic acid and change in abdominal aortic calcification over 3 years in postmenopausal women with osteoporosis: results from the HORIZON Pivotal Fracture Trial, Osteoporosis International, 31, (9) pp. 1741-1747. ISSN 0937-941X (2020) [Refereed Article]
Copyright Statement
Copyright 2020 International Osteoporosis Foundation and National Osteoporosis Foundation. This is a post-peer-review, pre-copyedit version of an article published in Osteoporosis International. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00198-020-05430-z
DOI: doi:10.1007/s00198-020-05430-z
Abstract
Introduction: Bisphosphonate use is associated with reduced risk of all-cause mortality and cardiovascular events. The underlying mechanisms are uncertain but may include effects on vascular calcification. This study aimed to evaluate the effect of zoledronic acid (ZA) on abdominal aortic calcification (AAC) in postmenopausal women with osteoporosis.
Methods: This was a post hoc analysis of the HORIZON Pivotal Fracture Trial that included 502 postmenopausal women (mean age 72.5 years) with osteoporosis (234 received ZA and 268 placebo). AAC scores (range, 0-8) were assessed from paired spine X-rays at baseline and after 3 years. Progression of AAC was defined as any increase in AAC score. The association between change in hip and femoral neck bone mineral density and change in AAC score was also assessed.
Results: At baseline, 292 (58.2%) participants had AAC (i.e., AAC score > 0), with AAC scores similar in the two intervention groups (median [interquartile range], 1 [0 to 2] for both; p = 0.98). Over 3 years, AAC progressed in a similar proportion of participants in both groups (ZA 29% and placebo 31%; p = 0.64). Change in bone mineral density and change in AAC score were not correlated.
Conclusion: Once-yearly zoledronic acid did not affect progression of AAC over 3 years in postmenopausal women with osteoporosis.
Item Details
| Item Type: | Refereed Article |
|---|---|
| Keywords: | aortic calcification, bisphosphonates, cardiovascular, osteoporosis, zoledronic acid |
| Research Division: | Biomedical and Clinical Sciences |
| Research Group: | Clinical sciences |
| Research Field: | Rheumatology and arthritis |
| Objective Division: | Health |
| Objective Group: | Clinical health |
| Objective Field: | Clinical health not elsewhere classified |
| UTAS Author: | Cai, G (Mr Guoqi Cai) |
| UTAS Author: | Aitken, D (Associate Professor Dawn Aitken) |
| UTAS Author: | Laslett, LL (Dr Laura Laslett) |
| UTAS Author: | Winzenberg, T (Professor Tania Winzenberg) |
| UTAS Author: | Jones, G (Professor Graeme Jones) |
| ID Code: | 139345 |
| Year Published: | 2020 |
| Web of Science® Times Cited: | 3 |
| Deposited By: | Menzies Institute for Medical Research |
| Deposited On: | 2020-06-10 |
| Last Modified: | 2021-05-25 |
| Downloads: | 1 View Download Statistics |
Repository Staff Only: item control page